ZMYND8 and prostate carcinoma: In mice injected with luciferase-expressing DU145 prostate cancer cells with ZMYND8 silencing by shRNA (shZMYND8), the luciferase signals were about five-fold higher than in those treated with the control shRNA, eight weeks after injection [8].